Product Reports Resources Pricing Login Book a demo
Fred Cohen
Person deep dive

Fred Cohen

#72 2026 Strebulaev–Jackson Venture Ranking, emerging firms

Fred Cohen is a physician-scientist who co-founded Monograph Capital, a life sciences firm, after co-founding TPG Biotechnology and Vida Ventures. He chaired Cell Design Labs when Gilead agreed to buy it for up to $567M in 2017 and sat on the board of Genomic Health, which Exact Sciences bought for $2.5B in 2019.

Founded
Monograph Capital, Vida Ventures
Education
Stanford University School of Medicine

Track record

Investments Fred Cohen is best known for, with what became of them.

Monograph Capital

FirmMonograph Capital
Founded2021
Based inSan Francisco, London and Fort Worth
FocusFounds and backs life sciences companies

Career

  1. Studied molecular biophysics at Yale, earned a DPhil at Oxford as a Rhodes Scholar and an MD at Stanford.
  2. Spent about 30 years at UCSF as a professor and chief of endocrinology and metabolism, publishing over 200 papers.
  3. 2001Co-founded TPG Biotechnology, which invested in over 50 life sciences companies during his 15 years there.
  4. 2017Co-founded Vida Ventures, a biotechnology investment firm.
  5. 2017Gilead and Kite agreed to buy Cell Design Labs, which he chaired, for up to $567M.
  6. 2019Exact Sciences completed its $2.5B purchase of Genomic Health, where he was a director.
  7. 2021Co-founded Monograph Capital with Charles Conn and became its chairman.

Sources: Yale Ventures — Fred Cohen · Gilead — Gilead and Kite to acquire Cell Design Labs (Dec 2017) · Exact Sciences 10-K FY2019 (Genomic Health purchase price) · Progyny — Board: Fred Cohen · Monograph Capital. Rank: 2026 Strebulaev–Jackson Venture Ranking.

Companies founded

Monograph Capital
Chairman · Founder · Partner · 2021 – present
Vida Ventures
Director · Founder · 2016 – present

Currently

Active roles, board seats and partnerships.

Zola Suite
CEO · 2015 – present
Keiretsu Forum
President
Mission Bay Capital
General Partner
Rapid Micro Biosystems
$32.8M valuation (2026)
→
TPG Biotech
Managing Director · Partner · Partner and Managing Director

Education

Stanford University School of Medicine
PhD · Medicine · 1980 – 1984
← All people